Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 73Neoplasm Metastasis 30Kidney Neoplasms 26Neoplasms 19Breast Neoplasms 14Prostatic Neoplasms 12Urinary Bladder Neoplasms 10Melanoma 9Gastrointestinal Stromal Tumors 9Brain Neoplasms 9Glioblastoma 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 7Liver Neoplasms 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Esophageal Neoplasms 5Colorectal Neoplasms 5Thyroid Neoplasms 4Solid Tumors 4Osteosarcoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Adenocarcinoma 4Uveal Melanoma 3Thymoma 3Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

fludarabine 2Paclitaxel 2Nivolumab 2Bevacizumab 2rucaparib 1liposomal doxorubicin 1dostarlimab 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Gemcitabine 1Erlotinib Hydrochloride 1Doxorubicin 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Clear Cell × Sunitinib × Clear all
NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Cathay General Hospital

Phase 2 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡